Combo trial data may boost early R&D
Today Probiodrug announced the results from a combination study of its lead Phase IIa product, glutaminylcyclase-inhibitor PQ912, and its specific monoclonal antibody PBD-C06, the company’s second asset in preclinical stage. This is the first preclinical proof-of-concept data and showed an additive effect of this two-pronged approach of inhibiting the formation and increasing the clearance of pyro-glutamyl-Amyloid beta (pGlu-Abeta), the toxic version of amyloid beta, potentially a key pathophysiological component in Alzheimer’s disease (AD). While PQ612 remains Probiodrug’s key asset, the encouraging preclinical findings in the combo study may boost the company’s earlier-stage programme, especially in light of Eli Lilly’s recent data from a Phase I study with a peer compound to PBD-C06 (see our outlook report).Vivoryon Therapeutics AG Formerly known as Probiodrug AG. Vivoryon Therapeutics AG, formerly Probiodrug AG, is a Germany-based biopharmaceutical company active in the biotechnology and medical research industry. The Company focuses on the development therapeutic products for the treatment of Alzheimer's disease. It develops drugs to target toxic pyroglutamate-Abeta (pGlu-Abeta) via two modes of action, namely by inhibiting the production of pGlu-Abeta and by clearing existing pGlu-Abeta from the brain. The Company develops specific inhibitors for the enzyme Glutaminyl Cyclase (QC) helping in the creation of pGlu-Abeta and engineers a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Its product pipeline comprises PQ912 and PQ1565, small molecule QC inhibitors, as well as PBD-C06, a pGlu-Abeta specific monoclonal antibody.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.